MCID: CNT030
MIFTS: 12

Central Nervous System Leiomyosarcoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leiomyosarcoma

MalaCards integrated aliases for Central Nervous System Leiomyosarcoma:

Name: Central Nervous System Leiomyosarcoma 12
Leiomyosarcoma of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5254
NCIt 47 C6999
UMLS 69 C1334385

Summaries for Central Nervous System Leiomyosarcoma

MalaCards based summary : Central Nervous System Leiomyosarcoma, is also known as leiomyosarcoma of the cns. The drugs Fentanyl and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include liver and brain.

Related Diseases for Central Nervous System Leiomyosarcoma

Symptoms & Phenotypes for Central Nervous System Leiomyosarcoma

Drugs & Therapeutics for Central Nervous System Leiomyosarcoma

Drugs for Central Nervous System Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
3
Ondansetron Approved Phase 3 99614-02-5 4595
4 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
5 Adjuvants, Anesthesia Phase 3
6 Analgesics Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics Phase 3
9 Anesthetics, General Phase 3
10 Anesthetics, Intravenous Phase 3
11 Central Nervous System Depressants Phase 3
12 Liver Extracts Phase 3,Phase 1
13 Narcotics Phase 3
14 Peripheral Nervous System Agents Phase 3
15 Anti-Anxiety Agents Phase 3
16 Antiemetics Phase 3
17 Anti-Inflammatory Agents Phase 3
18 Antineoplastic Agents, Hormonal Phase 3
19 Antipruritics Phase 3
20 Antipsychotic Agents Phase 3
21 Autonomic Agents Phase 3
22 BB 1101 Phase 3,Phase 2
23 Dermatologic Agents Phase 3
24 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
25 Gastrointestinal Agents Phase 3
26 glucocorticoids Phase 3
27 HIV Protease Inhibitors Phase 3
28 Hormone Antagonists Phase 3
29 Hormones Phase 3
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
31 Neurotransmitter Agents Phase 3
32
protease inhibitors Phase 3
33 Psychotropic Drugs Phase 3
34
Serotonin Phase 3 50-67-9 5202
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Tranquilizing Agents Phase 3
38 Cola Nutraceutical Phase 3,Phase 1
39
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
42
Promethazine Approved Phase 2 60-87-7 4927
43
Ifosfamide Approved Phase 2 3778-73-2 3690
44
Mechlorethamine Approved Phase 2 51-75-2 4033
45
Iodine Investigational Phase 2 7553-56-2 807
46 Alkylating Agents Phase 2
47 Anti-Infective Agents Phase 2,Phase 1
48 Antibodies Phase 2
49 Antibodies, Monoclonal Phase 2
50 Anti-Infective Agents, Local Phase 2

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
3 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
4 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
5 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
6 S9624 Ifosfamide in Treating Patients With Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
7 Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor Completed NCT00069940 Phase 1
8 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
9 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
10 Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection Withdrawn NCT00378781 Heparin;Minocycline-EDTA

Search NIH Clinical Center for Central Nervous System Leiomyosarcoma

Genetic Tests for Central Nervous System Leiomyosarcoma

Anatomical Context for Central Nervous System Leiomyosarcoma

MalaCards organs/tissues related to Central Nervous System Leiomyosarcoma:

39
Liver, Brain

Publications for Central Nervous System Leiomyosarcoma

Variations for Central Nervous System Leiomyosarcoma

Expression for Central Nervous System Leiomyosarcoma

Search GEO for disease gene expression data for Central Nervous System Leiomyosarcoma.

Pathways for Central Nervous System Leiomyosarcoma

GO Terms for Central Nervous System Leiomyosarcoma

Sources for Central Nervous System Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....